Arvinas (ARVN) to Announce Earnings on Wednesday

Posted by Brenda Bartman on Jul 29th, 2026

Arvinas (NASDAQ:ARVN – Get Free Report) is anticipated to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $60.7080 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:00 AM ET.

Arvinas (NASDAQ:ARVN – Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.05. The company had revenue of $15.60 million for the quarter, compared to analyst estimates of $16.61 million. Arvinas had a negative net margin of 247.54% and a negative return on equity of 44.38%. The firm’s quarterly revenue was down 91.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.14 EPS. On average, analysts expect Arvinas to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arvinas Price Performance

Arvinas stock opened at $8.20 on Wednesday. The firm has a fifty day simple moving average of $8.14 and a two-hundred day simple moving average of $10.44. Arvinas has a twelve month low of $6.05 and a twelve month high of $14.51. The company has a market capitalization of $529.06 million, a PE ratio of -2.48 and a beta of 1.74.

Analysts Set New Price Targets

Several equities research analysts have weighed in on ARVN shares. Stephens reiterated an “overweight” rating and issued a $18.00 price objective on shares of Arvinas in a report on Wednesday, June 3rd. Barclays upped their target price on Arvinas from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday, May 13th. Citigroup raised their price target on Arvinas from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Monday, May 4th. Zacks Research upgraded shares of Arvinas from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 26th. Finally, Weiss Ratings raised shares of Arvinas from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 13th. Eight investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $15.42.

Get Our Latest Research Report on ARVN

Insiders Place Their Bets

In other news, CFO Andrew Saik sold 11,139 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $9.94, for a total value of $110,721.66. Following the completion of the transaction, the chief financial officer owned 193,128 shares of the company’s stock, valued at approximately $1,919,692.32. This represents a 5.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Randy Teel sold 9,657 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $9.94, for a total value of $95,990.58. Following the transaction, the chief executive officer directly owned 287,218 shares of the company’s stock, valued at $2,854,946.92. This represents a 3.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 41,728 shares of company stock worth $402,649. Company insiders own 7.30% of the company’s stock.

Institutional Investors Weigh In On Arvinas

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARVN. Tower Research Capital LLC TRC boosted its holdings in shares of Arvinas by 491.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock worth $43,000 after buying an additional 4,835 shares during the last quarter. Canada Pension Plan Investment Board raised its position in Arvinas by 109.4% in the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock worth $49,000 after acquiring an additional 3,500 shares during the period. Jain Global LLC purchased a new position in shares of Arvinas during the 3rd quarter worth $95,000. Oxford Asset Management LLP increased its stake in shares of Arvinas by 15.5% in the 2nd quarter. Oxford Asset Management LLP now owns 16,705 shares of the company’s stock worth $123,000 after purchasing an additional 2,242 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Arvinas in the 3rd quarter worth $124,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

(Get Free Report)

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.